Ascentage Pharma

Forecast & Rating8 analysts currently cover Ascentage Pharma, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $47.13, about 215.4% upside from the current price of $14.94. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 100.0% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Ascentage Pharma closely still see room for the stock to rise. Data as of Sep 24, 2026; for reference only and not investment advice.